Vanguard Portfolio Management
BNTC icon

Vanguard Portfolio Management’s Benitec Biopharma BNTC Stock Holding History

Vanguard Portfolio Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Buy
143,510
+28,764
+25% +$341K ﹤0.01% 2745
2026
Q1 		$1.22M Buy
+114,746
New +$1.33M ﹤0.01% 2739

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Vanguard Portfolio Management's BNTC Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Benitec Biopharma (BNTC) stake by 25% in Q2 2026, buying an estimated $341K and bringing the position to 143,510 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

Vanguard Portfolio Management first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Vanguard Portfolio Management held 143,510 shares of Benitec Biopharma worth $1.92M as of Q2 2026.
  • Vanguard Portfolio Management bought 28,764 Benitec Biopharma shares in Q2 2026, an estimated $341K.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2745 holding.
  • Vanguard Portfolio Management first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.